ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALT Altimmune Inc

8.41
-0.35 (-4.00%)
Feb 20 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,755,666
Bid Price 8.38
Ask Price 8.50
News -
Day High 8.85

Low
2.09

52 Week Range

High
12.995

Day Low 8.32
Share Name Share Symbol Market Stock Type
Altimmune Inc ALT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.35 -4.00% 8.41 19:00:00
Open Price Low Price High Price Close Price Previous Close
8.53 8.32 8.85 8.40 8.76
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
20,493 2,755,666 US$ 8.52 US$ 23,481,639 - 2.09 - 12.995
Last Trade Type Quantity Price Currency
18:59:29 10 US$ 8.41 USD

Altimmune (ALT) Options Flow Summary

Overall Flow

Bullish

Net Premium

52k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Altimmune Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
451.86M 53.73M - -68k -84.71M -1.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Altimmune News

Date Time Source News Article
2/14/202411:04Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202405:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/05/202417:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/05/202417:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/05/202417:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/01/202417:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/01/202417:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/01/202417:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/01/202417:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/01/202417:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/29/202417:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/29/202417:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALT Message Board. Create One! See More Posts on ALT Message Board See More Message Board Posts

Historical ALT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week9.869.888.028.686,775,434-1.45-14.71%
1 Month9.9610.918.029.504,570,386-1.55-15.56%
3 Months3.0212.9952.897.5212,944,3545.39178.48%
6 Months2.6712.9952.097.046,429,1215.74214.98%
1 Year11.7612.9952.096.554,167,557-3.35-28.49%
3 Years22.5723.492.098.972,350,313-14.16-62.74%
5 Years2.9535.101.459.822,040,0495.46185.08%

Altimmune Description

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV).

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com